Primary open-angle glaucoma (POAG) is a major cause of irreversible blindness worldwide. We performed a genome-wide association study in an Australian discovery cohort comprising 1,155 cases with advanced POAG and 1,992 controls. We investigated the association of the top SNPs from the discovery stage in two Australian replication cohorts (932 cases and 6,862 controls total) and two US replication cohorts (2,616 cases and 2,634 controls total). Meta-analysis of all cohorts identified three loci newly associated with development of POAG. These loci are located upstream of ABCA1 (rs2472493[G], odds ratio (OR) = 1.31, P = 2.1 × 10 −19 ), within AFAP1 (rs4619890[G], OR = 1.20, P = 7.0 × 10 −10 ) and within GMDS (rs11969985[G], OR = 1.31, P = 7.7 × 10 −10 ). Using RT-PCR and immunolabeling, we show that these genes are expressed within human retina, optic nerve and trabecular meshwork and that ABCA1 and AFAP1 are also expressed in retinal ganglion cells.
POAG, the most common subtype of glaucoma, is characterized by a progressive loss of peripheral vision, but cases may remain undiagnosed until central vision is affected 1, 2 . The etiology and pathogenesis of POAG are poorly understood. Linkage studies, candidate gene studies and genome-wide association studies (GWAS) have identified several loci reproducibly associated with development of POAG [3] [4] [5] [6] [7] . Our previous GWAS of advanced POAG identified two loci at TMCO1 and CDKN2B-AS1 (ref. 6) , with studies of non-advanced POAG also having implicated CAV1 (ref. 5 ), SIX6 and a region at 8q22 (ref. 7) . Here we used a three-stage GWAS to identify additional genetic loci associated with POAG in participants of European descent.
The stage 1 discovery cohort comprised 1,155 cases with advanced glaucoma from the Australian and New Zealand Registry of Advanced Glaucoma (ANZRAG) and 1,992 controls genotyped on Illumina Omni1M or OmniExpress arrays (Supplementary Note and Supplementary Table 1 ). We combined and cleaned the genotype data from cases and controls and used 569,249 SNPs as the base of imputation against the 1000 Genomes phase 1 European-ethnicity data set. We successfully imputed 7,594,768 SNPs with minor allele frequency (MAF) >0.01 and imputation quality score >0.8.
Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma
We performed association analysis using an additive model adjusted for sex and six principal components. We corrected the P values from the association analysis for the estimated genomic inflation factor, λ, of 1.06 (the quantile-quantile plot is shown in Supplementary Fig. 1) .
The stage 1 association results across the genome are shown in Supplementary Figure 2 , and the association results for all SNPs with P < 1 × 10 −7 are shown in Supplementary Table 2 . Two previously unreported regions reached genome-wide significance (P < 5 × 10 −8 ) in the stage 1 discovery cohort, with a further previously unreported region showing association at close to genome-wide significance ( Table 1) . The top newly associated SNPs were rs2472493[G] upstream of ABCA1 (encoding ATP-binding cassette, subfamily A, member 1) on chromosome 9 (OR = 1.43, P = 2.0 × 10 −10 ), rs11827818[G] close to ARHGEF12 (encoding Rho guanine nucleotide exchange factor 12) (OR = 1.52, P = 9.2 × 10 −9 ) on chromosome 11 and rs114096562[A] in GMDS (encoding GDP-mannose 4,6-dehydratase) (OR = 1.55, P = 7.0 × 10 −8 ) on chromosome 6. The regional association results for these three SNPs are shown in Figure 1 . We also performed the analysis after removing controls affected by other diseases (Supplementary Note) and found that the effect sizes were similar ( Supplementary Table 3 ).
We then investigated the associations of top SNPs in the discovery cohort in a stage 2 set comprising two Australian replication data sets (the ANZRAG and Blue Mountains Eye Study (BMES) data sets, totaling 932 cases and 6,862 controls; Supplementary Note and Supplementary Table 1 ). All replication cohort participants were of European descent. To make maximum valid use of our cohorts, for replication we focused on SNPs directly genotyped on the Illumina Human610 and Human670 arrays; we used proxy genotyped SNPs Figure 1 Association results for the regions reaching genomewide significance. These plots show the regional association (using logistic regression with sex and the first six principal components fitted as covariates) and recombination rates for the top SNPs in the discovery data set (1,155 cases with advanced POAG and 1,992 controls). In each plot, the solid diamond indicates the topranked SNP in the region based on twosided P values. The colored box at the right or left corner of each plot indicates the pairwise correlation (r 2 ) between the top SNP and the other SNPs in the region. The blue spikes show the estimated recombination rates. The box underneath each plot shows the gene annotations in the region. Each plot was created using LocusZoom (http://csg.sph.umich.edu/locuszoom/) for the topranked SNP in each region with a 400kb region surrounding it. (a) The topranked SNP for this plot is rs2472493 on chromosome 9 upstream of ABCA1 with P = 2.0 × 10 −10 . (b) The topranked SNP for this plot is rs11827818 on chromosome 11 near ARHGEF12 with P = 9.2 × 10 −9 . (c) The topranked SNP for this plot is rs114096562 on chromosome 6 in GMDS with P = 7.0 × 10 −8 .
(d) This plot is centered on rs4619890 on chromosome 4 in AFAP1 with P = 9.7 × 10 −6 . This SNP clearly reached genomewide significance (P = 7.0 × 10 −10 ) in the metaanalysis of the results between the discovery and replication cohorts. l e t t e r S npg l e t t e r S where imputed data were not available for the replication cohorts (Online Methods). Examining all autosomal SNPs with P < 1 × 10 −4 in stage 1 (24 SNPs with the best P values were used as the lead SNPs; Supplementary  Table 4 ), four regions showed nominal evidence (P < 0.05 for seven SNPs in or near ABCA1, GMDS, ITIH1 and AFAP1) for replication in the ANZRAG replication samples ( Supplementary Table 4 ). When we combined stages 1 and 2, SNPs near ABCA1 and in AFAP1 exceeded genome-wide significance (P < 5 × 10 −8 for rs2472493 and rs4619890, respectively) with consistent effect sizes and directions of effects among the cohorts ( Table 2 and Supplementary Table 4 ).
In the stage 3 replication, we examined the newly identified top SNPs from stage 2 in data available from two additional replication cohorts (Supplementary Note and Supplementary Table 1 ): the National Eye Institute Glaucoma Human Genetics Collaboration (NEIGHBOR) and the Massachusetts Eye and Ear Infirmary (MEEI) (totaling 2,616 cases and 2,634 controls). We also performed a metaanalysis of the results for these SNPs between all cohorts (the discovery stage and all four replication cohorts) using the effect sizes and their standard errors. In the meta-analysis results, SNPs in or near ABCA1, AFAP1 and GMDS clearly reached genome-wide significance (P < 5 × 10 −8 ) ( Table 2) .
The top SNP within ARHGEF12 (rs2276035) did not reach the significance level (P < 5 × 10 −8 ) in our standard meta-analysis ( Table 2) , primarily because of heterogeneity between stage 1 and stages 2 and 3. This heterogeneity could be explained by the difference in glaucoma status in these cohorts, the 'winner's curse' effect that leads to inflated OR estimates in GWAS or chance. The top SNP within ITIH1 (rs2710323) was not genome-wide significant in our meta-analysis ( Table 2) .
At each of the newly discovered loci, the effect size was larger in the discovery cohort than in the replication cohorts ( Table 2) . The discovery cohort comprises cases with advanced POAG only, whereas the replication cohorts contained cases with POAG representing a range of disease severity. One cannot directly infer, however, that the true effect size is largest in advanced POAG. A winner's curse effect in the ANZRAG discovery cohort would inflate the OR estimates. Furthermore, there may have been greater diagnostic certainty in the cases with advanced POAG. To investigate further whether the newly discovered loci conferred higher risk in advanced compared to non-advanced POAG, we performed a subanalysis on the ANZRAG replication cohort. We found no consistent difference between the ORs for the cases with non-advanced (n = 605) and advanced (n = 220) POAG separately ( Supplementary Table 5 ). This subanalysis, together with the significant results in the replication cohorts taken alone, suggest that the newly discovered loci in this study are associated with POAG in general (and not advanced POAG only), indicating the generalizability of our findings.
Intraocular pressure (IOP) was not a criterion in the definition of POAG in this study because patients with POAG may have either normal or elevated IOP 8 . Thus, the new loci identified in this study are associated with POAG in general regardless of IOP levels. However, we had peak IOP measures available for 1,039 of the 1,155 cases in the ANZRAG discovery cohort. Of these cases, 330 (31.8%) had normaltension glaucoma (NTG) (IOP ≤ 21 mm Hg) and 709 (68.2%) had high-tension glaucoma (HTG) (IOP >21 mm Hg). We investigated the association of the new loci identified in this study in 330 cases with NTG and 709 cases with HTG compared to 1,992 population controls in the discovery cohort (Supplementary Table 6 ). The direction and magnitude of effects of the risk alleles were similar for NTG, HTG and all POAG ( Table 2 and Supplementary Table 6 ). However, the npg l e t t e r S analysis for NTG and HTG was less powerful compared to that for POAG because of the smaller sample sizes of the subgroups. None of our newly identified POAG loci overlapped with the previously published loci associated with POAG subphenotypes, including IOP and vertical cup-disk ratio [9] [10] [11] . We also investigated the association of the new loci identified in this study with peak measured IOP in 1,039 cases with POAG with available data in the ANZRAG discovery cohort. The new loci were not associated with peak IOP in the ANZRAG discovery cohort (Supplementary Table 7) , although the ABCA1 SNP showed a trend toward significance (P = 0.0675, two-sided test). The ABCA1 glaucoma risk-increasing allele acts in the expected direction on IOP (the allele increases IOP), resulting in a P value of 0.034 in a one-sided test. Larger sample sizes and further meta-analyses of multiple studies will unambiguously determine whether the new loci identified in this study are associated with subphenotypes such as IOP.
We also investigated previously reported GWAS hits identified in other studies [5] [6] [7] in the meta-analysis of results between our discovery and replication cohorts (Supplementary Table 8 ). The TMCO1, CDKN2B-AS1 and SIX6 loci were clearly genome-wide significant (P < 5 × 10 −8 ), whereas CAV1-CAV2 and the locus on chromosome 8 were associated with POAG but not at a genome-wide significance level. SNP rs11669977 at NTF4 was not associated with POAG in our meta-analysis.
We used ENCODE project data 12 and the Genevar database 13 (expression quantitative trait locus (eQTL) database) to predict the possible functional effects of the top SNPs identified in this study. The top SNP rs2472493 located upstream of ABCA1 is an eQTL in lymphoblastoid cell lines (Genevar database) and may alter the sequence of motifs for proteins such as FOXJ2 and SIX5 (HaploReg v2) 14 . One of the SNPs in high linkage disequilibrium (LD, r 2 > 0.8) with the top SNP near ABCA1 (rs2472494) alters the regulatory motif for binding of PAX6 (HaploReg v2). PAX6 is an established master control gene in eye development 15 . A SNP (rs28495790) in high LD (r 2 > 0.8) with the best SNP in AFAP1 (rs4619890) is likely to affect the binding of proteins (score 2b in RegulomeDB) 16 such as CTCF and RAD21 in a variety of cell lines, including WERI-Rb-1 (retinoblastoma). rs28495790 alters the sequence of regulatory motifs for binding of several proteins, including PAX6 (HaploReg v2). This may suggest a regulatory role for this SNP in gene expression in a pathway similar to that of rs2472494 near ABCA1. In GMDS, rs3046543 (in high LD, r 2 = 0.8, with the top imputed SNP rs114096562) alters the sequence of the regulatory motif for binding of SIX6; SIX6 variants confer glaucoma risk 7 . SNPs close to SIX6 also clearly reached genome-wide significance in our meta-analysis (top SNP rs10483727[T], OR = 1.32, P = 1.56 × 10 −17 ). These data suggest that the top SNPs identified in this study may have important regulatory roles.
ABCA1 is a membrane-bound receptor involved in phospholipid and cholesterol efflux from cells. In monkey retinas, ABCA1 is expressed in retinal ganglion cells 17 , the cells that undergo apoptosis in glaucoma. We analyzed the expression of ABCA1 mRNA in human ocular tissues by RT-PCR and found that the iris, ciliary body, retina, optic nerve head, optic nerve and trabecular meshwork cell lines derived from normal and glaucomatous eyes expressed the main transcript that encodes the full-length protein ( Supplementary  Fig. 3a) . We also detected an alternative transcript in the ocular tissues ( Supplementary Fig. 3a ) that had unknown function 18, 19 . Immunolabeling of sections of normal human eye with ABCA1specific antibody (Supplementary Fig. 4 ) showed a distribution of the protein in the trabecular meshwork, all layers of the retina (including retinal ganglion cells) and the optic nerve (Fig. 2) . We observed similar ABCA1 labeling in a glaucomatous eye, including in the layers of the retina (Fig. 2g) . ABCA1 has been reported to regulate neuroinflammation and neurodegeneration through coordinated activity in various cell types in mouse brains 20 , and it may be involved in glaucoma through a similar function in the retina.
AFAP1 encodes a protein that binds to actin filaments and allows their crosslinking 21, 22 . Actin cytoskeleton-modulating signals have been shown to be involved in the regulation of aqueous outflow and (a-f) Sections of a normal human eye were immunolabeled with the ABCA1specific antibody (brown) and counterstained with haematoxylin to visualize nuclei (blue). Positive immunolabeling was detected in the trabecular meshwork (a,b), throughout the retina (c,d) and in the optic nerve (e,f). In the retina (c), comparatively pronounced ABCA1 immunolabeling was observed at the tips of photoreceptors and in the outer limiting membrane (OLM), outer plexiform layer (OPL) and nerve fiber layer (NFL). (d) Labeling was also pronounced in some cells in the inner nuclear layer (INL, arrows), in retinal ganglion cells in the ganglion cell layer (GCL, arrowhead) and in the retinal blood vessel wall (not shown). In the optic nerve (e,f), the protein was distributed in the nerve fiber bundles (e, asterisk) and at the cell boundary of astrocytes in the glial columns (f, arrows). (g,h) In sections of a glaucomatous eye (data not shown), including in the retina (g), similar distribution of the protein to that in the normal eye was observed. The experiment was repeated once for reproducibility. (h) Section hybridized with the secondary detection reagent alone as a negative control. SC, Schlemm's canal; RPE, retinal pigment epithelium; OS, outer segment; IS, inner segment; ONL, outer nuclear layer; IPL, inner plexiform layer. Scale bars, 100 µm. l e t t e r S intraocular pressure [23] [24] [25] , which are important parts of glaucoma pathogenesis. AFAP1 encodes two isoforms, the neuronal cell-specific A isoform and the ubiquitously expressed B isoform. By RT-PCR, we detected expression of both the A and B isoforms in human retina (Supplementary Fig. 3c ) and expression of the B isoform in other ocular tissues, including the iris, ciliary body, lens, optic nerve and optic nerve head, as well as in cultured trabecular meshwork cells (Supplementary Fig. 3b) . Consistent with the mRNA expression data, we observed AFAP1-positive immunolabeling in the trabecular meshwork, retina (including retinal ganglion cells) and optic nerve of normal human eye (Supplementary Fig. 5 ) using AFAP1-specific antibody (Supplementary Fig. 6 ). We observed similar AFAP1 labeling in a glaucomatous eye, including in the retina ( Supplementary  Fig. 5g,h) . These data indicate that the function of AFAP1 in the trabecular meshwork and retina may be relevant in the pathogenesis of glaucoma.
GMDS encodes a protein that is required for the first step in de novo synthesis of fucose 26 . Fucose is required for diverse biological functions, including growth factor receptor signaling 27 . Several studies have suggested effects of growth factors on the development of glaucoma 23, [28] [29] [30] [31] [32] . GMDS expresses two variant transcripts, 1 and 2. We detected expression of the variant 1 transcript in human ocular tissues and cultured trabecular meshwork cells by RT-PCR ( Supplementary Fig. 3d ), which indicates ubiquitous expression of the gene in the eye.
In this study we identified three new risk loci for POAG and highlighted related candidate genes and pathways that might be involved in developing POAG. These new loci, in addition to the previously known risk loci, will improve risk profiling for glaucoma, with better opportunities for the management of high-risk individuals. Currently, many cases of glaucoma remain undiagnosed until severe visual loss occurs; early detection and treatment can slow disease progression and prevent blindness 33 . Further dissection of these new POAG risk loci will likely lead to insights into the etiology of this common, irreversible cause of blindness.
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